Literature DB >> 8972757

DNA ploidy and MYC DNA amplification in ovarian carcinomas. Correlation with p53 and bcl-2 expression, proliferative activity and prognosis.

J Diebold1, B Suchy, G B Baretton, S Blasenbreu, W Meier, M Schmidt, H Rabes, U Löhrs.   

Abstract

There is increasing evidence that DNA ploidy is a prognostic factor in ovarian carcinomas, but it is uncertain whether MYC DNA amplification is an epiphenomenon of DNA nondiploidy or a distinct biological change with an impact on the clinical course of the disease. To clarify these issues we analysed DNA ploidy by flow and image cytometry and MYC copy number by polymerase chain reaction in archival material from ovarian carcinomas with known follow up. The results were compared with proliferative activity (Ki67 index) and p53 and bcl-2 expression. DNA cytometry revealed nondiploidy in 84 of 144 cases (58.3%). Nondiploidy was statistically significantly correlated with histological tumour type, histological grade, Ki67 index > 10%, FIGO stage, presence of residual tumour after debulking surgery and adverse postoperative outcome. Furthermore, DNA nondiploidy was associated with p53 accumulation. We found that 84.9% of the p53-positive cases were nondiploid. This points to the paramount importance of wild type p53 for the maintenance of genome integrity in this tumour type. MYC DNA amplification was seen in 33.8% (26/77 cases) of ovarian carcinoma. There was no correlation between MYC DNA amplification and histological tumour type, histological grade, FIGO stage, DNA ploidy, proliferative activity or prognosis. However, when p53 and bcl-2 expression was taken into account, a statistically significant correlation between gene alteration or expression patterns and histological tumour type was revealed. The group of mucinous carcinomas demonstrated both MYC DNA amplification and strong bcl-2 expression in 50% and contained the largest fraction of cases without aberration (37.5%). Endometrioid carcinomas were characterized by strong bcl-2 expression in 85%, whereas serous and undifferentiated carcinomas predominantly exhibited p53 alterations, frequently accompanied by bcl-2 overexpression or MYC DNA amplification. Thus, in interaction with other genes MYC DNA amplification may play a role in the determination of the varying differentiation patterns of ovarian carcinomas.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8972757     DOI: 10.1007/bf00198337

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  41 in total

1.  Molecular genetic detection of Xp21 muscular dystrophy carriers in Cyprus.

Authors:  K Christodoulou; P Ioannou; L Middleton
Journal:  Biomed Pharmacother       Date:  1994       Impact factor: 6.529

2.  Tumour ploidy, morphometry, histological grading and clinical features in ovarian carcinoma: mutual relations.

Authors:  H Haapasalo; N B Atkin; Y Collan; E Pesonen; L Paljärvi
Journal:  Anal Cell Pathol       Date:  1991-09       Impact factor: 2.916

3.  Determination of N-myc gene amplification in neuroblastoma by differential polymerase chain reaction.

Authors:  J Gilbert; M D Norris; M Haber; M Kavallaris; G M Marshall; B W Stewart
Journal:  Mol Cell Probes       Date:  1993-06       Impact factor: 2.365

4.  A unique pattern of proto-oncogene abnormalities in ovarian adenocarcinomas.

Authors:  D J Zhou; N Gonzalez-Cadavid; H Ahuja; H Battifora; G E Moore; M J Cline
Journal:  Cancer       Date:  1988-10-15       Impact factor: 6.860

5.  Deoxyribonucleic acid ploidy in seminomas with and without syncytiotrophoblastic cells.

Authors:  G Baretton; J Diebold; T DePascale; R Bussar-Maatz; L Weissbach; U Löhrs
Journal:  J Urol       Date:  1994-01       Impact factor: 7.450

6.  bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas.

Authors:  J Diebold; G Baretton; M Felchner; W Meier; K Dopfer; M Schmidt; U Löhrs
Journal:  Am J Clin Pathol       Date:  1996-03       Impact factor: 2.493

Review 7.  Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators.

Authors:  B W Stewart
Journal:  J Natl Cancer Inst       Date:  1994-09-07       Impact factor: 13.506

8.  p53 gene mutations and protein accumulation in human ovarian cancer.

Authors:  J Kupryjańczyk; A D Thor; R Beauchamp; V Merritt; S M Edgerton; D A Bell; D W Yandell
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

Review 9.  Gene amplification and tumor progression.

Authors:  O Brison
Journal:  Biochim Biophys Acta       Date:  1993-05-25

10.  Protooncogene amplification and tumor ploidy in human ovarian neoplasms.

Authors:  H Sasano; C T Garrett; D S Wilkinson; S Silverberg; J Comerford; J Hyde
Journal:  Hum Pathol       Date:  1990-04       Impact factor: 3.466

View more
  9 in total

1.  [Molecular pathology of epithelial ovarian neoplasias: from the phenotype-genotype correlation to new targets in diagnostics and therapy].

Authors:  A Staebler; J Diebold
Journal:  Pathologe       Date:  2007-05       Impact factor: 1.011

2.  Role of beta-catenin/T-cell factor-regulated genes in ovarian endometrioid adenocarcinomas.

Authors:  Yali Zhai; Rong Wu; Donald R Schwartz; Danielle Darrah; Heather Reed; Frank T Kolligs; Marvin T Nieman; Eric R Fearon; Kathleen R Cho
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

3.  Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma.

Authors:  Peter Schraml; Georg Schwerdtfeger; Felix Burkhalter; Anna Raggi; Dietmar Schmidt; Teresa Ruffalo; Walter King; Kim Wilber; Michael J Mihatsch; Holger Moch
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

4.  Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors.

Authors:  E W Newcomb; M Sosnow; R I Demopoulos; A Zeleniuch-Jacquotte; J Sorich; J L Speyer
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

5.  Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study.

Authors:  Kathleen M Darcy; William E Brady; Jan K Blancato; Robert B Dickson; William J Hoskins; William P McGuire; Michael J Birrer
Journal:  Gynecol Oncol       Date:  2009-06-12       Impact factor: 5.482

6.  miRNA profiling along tumour progression in ovarian carcinoma.

Authors:  Olga Vaksman; Helene Tuft Stavnes; Janne Kaern; Claes G Trope; Ben Davidson; Reuven Reich
Journal:  J Cell Mol Med       Date:  2011-07       Impact factor: 5.310

7.  Clinical Importance of Myc Family Oncogene Aberrations in Epithelial Ovarian Cancer.

Authors:  MoonSun Jung; Amanda J Russell; Catherine Kennedy; Andrew J Gifford; Kylie-Ann Mallitt; Siva Sivarajasingam; David D Bowtell; Anna DeFazio; Michelle Haber; Murray D Norris; Michelle J Henderson
Journal:  JNCI Cancer Spectr       Date:  2018-11-16

Review 8.  c-MYC and Epithelial Ovarian Cancer.

Authors:  Jeyshka M Reyes-González; Pablo E Vivas-Mejía
Journal:  Front Oncol       Date:  2021-02-26       Impact factor: 6.244

9.  Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses.

Authors:  J Blancato; B Singh; A Liu; D J Liao; R B Dickson
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.